The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The submission is supported by findings from the phase III SUNMO trial evaluating the subcutaneous formulation of mosunetuzumab alongside intravenous polatuzumab vedotin for
Developed by Mabwell's wholly owned subsidiary T-mab, this new clearance specifically covers the use of the drug in reducing severe skeletal-related complications like
The investigational Cytotoxicity Targeting Chimera targets the CCR2 receptor, highly expressed on malignant monocytes and bone marrow blasts to selectively eliminate disease-driving cells.
At the 2026 ASCO Annual Meeting, Marc Hoffman, MD, of the University of Kansas Cancer Center, discusses results from the ongoing GOLSEEK-1 trial
Dr. Usmani and Mina discuss the pivotal phase 3 MajesTEC-9 trial evaluating teclistamab monotherapy for patients with relapsed/refractory multiple myeloma who were previously
Hans Lee, MD, director of Myeloma Research at the Sarah Cannon Research Institute, discusses an early phase 1/2 clinical trial evaluating the investigational
The US Food and Drug Administration has granted Orphan Drug Designation to EO2463 immunotherapy for the treatment of patients with indolent non-Hodgkin lymphoma
The Phase 1 trial evaluates DuoCAR20.19.22-D95 in adults with relapsed or refractory B-cell malignancies who have often failed prior CAR T-cell treatments.
In this session from the SOHO Insider Community Oncology Brown Bag series, Luke Fletcher, MD, presents on an exploration of barriers and solutions
The discussion also covers the study's safety profile and the potential for these early-stage immunotherapies to achieve long-term curative results.
